Merck/Ariad’s Hopes For Ridaforolimus May Rest Beyond Sarcoma After FDA Rejection
This article was originally published in The Pink Sheet Daily
Executive Summary
In a “complete response” letter, the agency said it wanted more clinical data on use of the mTOR inhibitor as a maintenance therapy in metastatic soft tissue or bone sarcoma. Merck says it is confident in ridaforolimus’ potential and points to an active development program in various solid tissue cancers.